A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...

A therapy that would once have been considered a feat of science fiction has reversed aggressive and incurable blood cancers ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

In January, Aldevron unveiled its Alchemy cell-free DNA technology. Instead of using cells to produce DNA, Alchemy relies on enzymes to produce linear DNA that serves as a template for the synthesis ...

Donor-derived cell-free DNA can aid detection, diagnosis, and monitoring of antibody-mediated rejection after kidney transplantation. Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker ...

Aldevron unveiled Alchemy™ cell-free DNA technology. The technology was designed to support development and preclinical programs, with a future cGMP offering expected to launch in 2025 to support ...